Sierra Oncology Reports Results of Momelotinib in P-III (MOMENTUM) Study for the Treatment of Myelofibrosis
Shots:
- The P-III (MOMENTUM) study evaluating momelotinib vs danazol in 195 patients with myelofibrosis who were symptomatic & anemic across 21 countries. The company is expected the NDA submission in Q2’22
- The trial met all 1EPs & 2EPs i.e., patients achieved benefit on symptoms, anemia & splenic size, TSS reduction of >50% (25% vs 9%), transfusion independence (31% vs 20%), SRR >35% (23% vs 3%), rate of Grade 3 or worse AEs (54% & 65%), serious TEAEs were 35% & 40%
- Additionally, mean baseline characteristics for all patients were TSS of 27, Hgb of 8 g/dL & platelet count of 145 x 10 9/L. Momelotinib is a potent, selective & orally bioavailable JAK1/2 & ACVR1/ALK2 inhibitor
Ref: Businesswire | Image: Sierra
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com